(Q35782650)

10 August 2017

1 reference

title

Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines (English)

1 reference

10 August 2017

0 references

Luis Jódar

1

1 reference

10 August 2017

Elwyn Griffiths

series ordinal

2

1 reference

10 August 2017

Ian Feavers

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

22

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

1047-1053

1 reference

Manson Lecture. Meningococcal meningitis in Africa

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

7 January 2021

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Development of vaccines against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Human immunity to the meningococcus. II. Development of natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Cutaneous Reactions and Antibody Response to Meningococcal Group C Polysaccharide Vaccines in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Prevention of Meningococcal Disease by Group C Polysaccharide Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Potential and limitations of polysaccharide vaccines in infancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Lot-release criteria, postlicensure quality control, and the Haemophilus influenzae type b conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

WHO/NIBSC-Co-sponsored Informal Workshop on the Use of Physicochemical Methods for the Characterization of Haemophilus influenzae type b Conjugate Vaccines. NIBSC, U.K., 22-23 June 1998. National Institute for Biological Standards and Control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Comparative Immunogenicity of Vaccines Prepared from Capsular Polysaccharides of Group C Neisseria meningitidis O.Acetyl.Positive and O.Acetyl.Negative Variants and Escherichia coli K92 in Adult Volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Meningococcal polysaccharide vaccination of military recruits in Israel: preliminary assessment of vaccine effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Epidemiological pattern of meningococcal disease in Valencia, Spain. Impact of a mass immunization campaign with meningococcal C polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Effectiveness of a mass immunization campaign against serogroup C meningococci in children in the federal state of Santa Catarina, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Assay parameters and methods of data analysis for the comparison of complement sources in the Neisseria meningitidis serogroup C serum bactericidal assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Pediatric combination vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Immunogenicity and safety of mixed DTP/IPV/Hib vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.08.040

1 reference

10 August 2017

1 reference